SoluLinK Appoints David McCarty to Its Board of Directors

Jun 06, 2006, 01:00 ET from SoluLinK, Inc.

    SAN DIEGO, June 6 /PRNewswire/ -- SoluLinK, Inc. a leader in
 biomolecular conjugation products and services for life science,
 diagnostic, and nanotechnology markets, announced today the appointment of
 David McCarty to its Board of Directors.
     Mr. McCarty is currently the President and CEO of PanCel. He has held
 senior positions in the health care industry for over 30 years. Most
 recently, Mr. McCarty was President and CEO of NOVEX, which he successfully
 merged with Invitrogen (a publicly-traded research products company) in
 August 1999. He served on the Board of Directors of Invitrogen from August
 1999 to August 2004. Prior to joining NOVEX in 1997, Mr. McCarty was the
 President and CEO of Alexon Biomedical, a medical diagnostics company,
 which he led to a successful financial turnaround and a profitable
 strategic sale to Sybron International (now Apogent Technologies) in early
 1997. His other professional experience includes senior operating positions
 at Gen-Probe, Allergenetics, Calbiochem-Behring, Boehringer Mannheim
 Diagnostics, and Hyland Diagnostics. Mr. McCarty received his B.S. in
 chemistry from California State University at Northridge and his M.B.A.
 from California State University at Long Beach.
     "It is an honor to have David McCarty join SoluLinK's board. He is a
 proven leader and brings market savvy and practical business expertise to
 SoluLinK from his successful experience managing and directing multiple
 bioscience companies," stated Steve DeGraw President and Chief Business
 Officer of SoluLinK. "His knowledge of all aspects of the management of
 rapidly growing life science companies will be invaluable to SoluLink's
 continued growth."
     About SoluLinK
     SoluLinK is a privately held company located in San Diego, California.
 SoluLinK develops, manufactures and markets products and services for the
 conjugation of proteins, oligonucleotides, peptides, and antibodies to one
 another, and to solid surfaces for array, research assay, diagnostic, and
 therapeutics applications. SoluLinK's biotinylation reagent ChromaLink(R)
 is an example of such products that that create, improve, and enable the
 performance of arrays, research assays, diagnostics, and certain types of
 therapeutics. SoluLinK markets these products directly and through
 distributors and licensing partners world-wide.

SOURCE SoluLinK, Inc.